Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'

Human Immunodeficiency Virus Clinical Trial

— BIC-T&T  

Official title:

Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04653194
• Other study ID #: CRF002
• Secondary ID: 2019-003208-11
• Status: Completed
• Phase: Phase 3
• Start date: September 30, 2020
• Est. completion date: July 31, 2023

Study information

• Verified date: January 2024
• Source: Chelsea and Westminster NHS Foundation Trust
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The administration of combination antiretroviral therapy (cART) to HIV-infected patients has been associated with a dramatic reduction in AIDS-related morbidity and mortality. Time to cART start is currently approximately 2-4 weeks after diagnosis, mostly deferred for reasons of waiting for baseline blood test results; in particular HIV genotype, CD4 count, OI screen and logistics of a consultant clinical review. Whilst there is a clear rationale for this delay there is a risk of loss to follow-up as well as the potential risk of onward viral transmission. The balance between "readiness" to start ART against pragmatic and practical safe initiation of treatment needs to be tested using currently available safe potent antiretroviral agents in a head-to-head comparison study to allow careful rigorous comparisons of outcomes.

This study will recruit 36 newly diagnosed HIV patients to be started on treatment immediately upon diagnosis. This would optimally be within 7 days, for eligibility to the study up to 14 days will be permissible. Patients will be randomised to one of two open-label combination therapies known to be highly effective; Biktarvy or Symtuza. The patients will receive study treatment for 48 weeks. The two therapies will be compared by the change in HIV viral load from start of treatment to 12 weeks. Further clinical data will be recorded for the trial patients and exploratory investigations undertaken. As those recruited to the trial may not be representative of the full cohort of newly diagnosed HIV patients there will also be data collected on all newly diagnosed patients in a given period. This data will contribute to conclusions on the benefits and issues of implementing test and treat.

Description:

There will be an open-label two arm clinical trial with participants randomised to Biktarvy or Symtuza with equal probability. Study treatment will last for 48 weeks.

Baseline - Following confirmatory HIV testing potential participants will have a appointment with a study doctor. Full medical check and medical history undertaken. Patients will be offered opportunity to participate in the study. To avoid unnecessary visits and in line with the study aim of getting patients on treatment rapidly patients can consent on the same day that HIV diagnosis is confirmed to them. Treatment to be initiated following appointment in line with test and treat procedure. Samples will be taken (if not available from previous days) for all initial required tests.

Participants will be given baseline questionnaires that they can return on week 2 visit.

Week 1 call - Call to check drug adherence, adverse events and patient wellbeing.

Week 2 visit - Appointment with study doctor to review all results from initial tests. Following undertaken: viral load; vital signs; adverse events; adherence assessment.

Week 4, 12, 24, 48 Follow-up visits - Full medical review undertaken at each visit including safety blood tests.

Following undertaken: viral load; adverse events; adherence assessment; questionnaires; samples taken for secondary and exploratory objectives. Week 48 visit will be the end of study treatment period.

Follow-up visit - up to 30 days after the week 48 visit there will be a follow-up visit to complete final medical assessment and final adverse events reporting.

Samples will be collected from participants further to those required for stated objectives to be retained for future research into HIV infection.

We will also collect and clinical data cohort of data on all patients newly diagnosed with HIV during a set window.

Clinical data will be collected from their first year after diagnosis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: July 31, 2023
• Est. primary completion date: July 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Is male or female aged 18 years or over.

2. Confirmed diagnosis of HIV-1 as per local clinic definition less than 14 days before day treatment is to be initiated.

3. Is capable of giving informed consent.

4. Is willing to comply with the protocol requirements

5. A female may be eligible to enter and participate in the study if she:

1. is of non-child-bearing potential defined as either post-menopausal (12 months of spontaneous amenorrhea and = 45 years of age) or physically incapable of becoming pregnant with documented tubal ligation, hysterectomy or bilateral oophorectomy or,

2. is of child-bearing potential with a negative pregnancy test at Screening (& baseline visit) and agrees to use one of the methods of contraception to avoid pregnancy indicated in Appendix 4 during the study and for a period of 12 weeks after the study.

6. Men who have partners who are women of childbearing potential (WOCBP - definition in Appendix 4) must be using an adequate method of contraception as listed in Appendix 4 to avoid pregnancy in their partner throughout the study and for a period of at least 12 weeks after the study;

Exclusion Criteria:

1. Infected by HIV-2

2. On PEP

3. Use of medications that are know to interact with either treatment B or S

4. Unstable health conditions that according to the opinion of the Investigator suggest the individual should not take part in the trial (including unstable liver diseases, possible opportunistic infections, etc)

5. Women planning pregnancy or who are pregnant or breast feeding. (NB: See section 4.4; Withdrawal Criteria and Section 10.4; Collection and Follow up of Adverse Events if pregnancy does occur in a trial subject)

6. Ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical intraepithelial neoplasia; other localized malignancies require agreement between the investigator and the Study medical monitor for inclusion of the subject prior to randomisation.

7. Known acute or chronic viral hepatitis including, but not limited to, A, B, or C

8. Any investigational drug within 30 days prior to the trial drug administration

9. Any other condition (including illicit drug use or alcohol abuse) or laboratory results which, in the investigator's opinion, interfere with assessments or completion of the trial.

Related Conditions & MeSH terms

• Acquired Immunodeficiency Syndrome
• HIV Infections
• Human Immunodeficiency Virus

Intervention

Drug:
• Biktarvy
Combination single tablet anti-retroviral therapy: bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg
• Symtuza
Combination single tablet anti-retroviral therapy: darunavir 800mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg

Locations

Country	Name	City	State
United Kingdom	Brighton and Sussex University Hospitals NHS Trust Lawson Unit Royal Sussex County Hospital	Brighton
United Kingdom	Chelsea and Westminster Hospital NHS Foundation Trust	London
United Kingdom	Imperial College Healthcare NHS Trust	London

Sponsors (3)

Lead Sponsor	Collaborator
Chelsea and Westminster NHS Foundation Trust	Gilead Sciences, Imperial College London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of HIV viral load response to first-line anti-retroviral treatment	Change from baseline to week 12 in log10 HIV RNA level recorded in viral load assays.	Baseline to 12 weeks
Secondary	Absolute efficacy in achieving viral suppression of newly diagnosed HIV infection.	Proportion of participants achieving viral suppression at study visits as defined both by HIV copies < 20/ml and HIV copies < 50 ml	2 weeks, 4 weeks, 12 weeks, 24 weeks, 48 weeks
Secondary	Adverse events occurrence	Frequency and severity of occurrence of adverse events in study participants	Baseline to 48 weeks
Secondary	Viral resistance occurrence	Frequency of occurrence of confirmed viral resistance to study interventions	Baseline to 48 weeks